Blood Pressure Control with Amlodipine Add-on Therapy in Patients with Hypertension and Diabetes: Results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial
Restricted accessResearch articleFirst published online November, 2008
Blood Pressure Control with Amlodipine Add-on Therapy in Patients with Hypertension and Diabetes: Results of the Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial
Attainment of blood pressure (BP) goals in patients with diabetes is critical both to reduce the risk of cardiovascular events and to delay the progression of renal disease. While therapeutic guidelines advise initial therapy with an angiotensin-converting enzyme inhibitor or angiotensin receptor blocker, monotherapy with these agents may not be sufficient to attain target BP.
Objective:
The ADHT (Amlodipine Diabetic Hypertension Efficacy Response Evaluation Trial) evaluated the efficacy and safety of adding amlodipine to the treatment regimen of patients with hypertension and diabetes who were already receiving either quinapril or losartan as monotherapy.
Methods:
ADHT was a double-blind, double-dummy, 22-week trial conducted in the US, After a washout period of 7–13 days, patients (aged 30–75 y) with hypertension and diabetes were randomized to receive quinapril 20 mg/day plus placebo or losartan 50 mg/day plus placebo for 4 weeks, titrated to 40 mg or 100 mg (if required), respectively, for an additional 4 weeks to achieve their BP goals (<130/60 mm Hg), At week 8, either amlodipine 5 mg/day or placebo was added for an additional 12 weeks, with titration to 10 mg at week 14 if the BP goal was not achieved.
Results:
Efficacy of add-on therapy was evaluated in 411 patients (amlodipine 211, placebo 200). BP goal was reached by 27.5% of patients when amlodipine was added to quinapril or losartan monotherapy, compared with 12.5% when placebo was added (OR 2.73; 95% CI 1.61 to 4.64; p < 0.001), When added to quinapril or losartan monotherapy, amlodipine reduced BP by 8.1/5.4 mm Hg, compared with a 1.6/0.7 mm Hg decrease with add-on placebo (p < 0.001). Amlodipine, quinapril, and losartan were well tolerated.
Conclusions:
Amlodipine is safe and effective when added to quinapril or losartan monotherapy to help lower BP toward therapeutic targets in patients with hypertension and diabetes.
SowersJR, EpsteinM, FrohlichED. Diabetes, hypertension, and cardiovascular disease: an update. Hypertension2001; 37: 1053–9.
2.
ZanellaMT, KohlmannOJr, RibeiroAB. Treatment of obesity hypertension and diabetes syndrome. Hypertension2001; 38: 705–8.
3.
StamlerJ, VaccaroO, NeatonJD, WentworthD.Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the Multiple Risk Factor Intervention Trial. Diabetes Care1993; 16: 434–44.
4.
VijanS, HaywardRA. Treatment of hypertension in type 2 diabetes mellitus: blood pressure goals, choice of agents, and setting priorities in diabetes care. Ann Intern Med2003; 138: 593–602.
5.
UK Prospective Diabetes Study (UKPDS) Group.Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ1998;317: 703–13.
6.
HanssonL, ZanchettiA, CarruthersSGEffects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. HOT Study Group. Lancet1998; 351: 1755–62.
7.
TuomilehtoJ, RastenyteD, BirkenhagerWHEffects of calcium-channel blockade in older patients with diabetes and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. N Engl I Med1999; 340: 677–84.
8.
UK Prospective Diabetes Study (UKPDS) Group.Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). Lancet1998;352: 837–53.
9.
CasasJP, ChuaW, LoukogeorgakisSEffect of inhibitors of the renin-angiotensin system and other antihypertensive drugs on renal outcomes: systematic review and meta-analysis. Lancet2005; 366: 2026–33.
ChobanianAV, BakrisGL, BlackHRThe Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: The JNC 7 Report. JAMA2003; 289: 2560–72.
12.
American Diabetes Association.Standards of medical care in diabetes-2008. Diabetes Care2008;31(suppl 1):S12–54.
13.
Kidney Disease Outcomes Quality Initiative (K/DOQI).K/DOQI clinical practice guidelines on hypertension and antihypertensive agents in chronic kidney disease. Am J Kidney Dis2004;43: S1–290.
14.
GrantRW, BuseJB, MeigsJB. Quality of diabetes care in US academic medical centers: low rates of medical regimen change. Diabetes Care2005; 28: 337–42.
15.
JohnsonML, PietzK, BattlemanDS, BeythRJ. Therapeutic goal attainment in patients with hypertension and dyslipidemia. Med Care2006; 44: 39–46.
16.
SwislockiA, NothRH, VolppB, MeierJ, SiegelD.Blood pressure control in a diabetic population assessed by computer review. J Hum Hypertens2006; 20: 540–2.
17.
ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group.Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA2002;288:2981–97.
18.
JuliusS, KjeldsenSE, WeberMOutcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial. Lancet2004; 363: 2022–31.
19.
BakrisGL, WilliamsM, DworkinLPreserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis2000; 36: 646–61.
20.
DahlofB, SeverPS, PoulterNRPrevention of cardiovascular events with an antihypertensive regimen of amlodipine adding Perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet2005; 366: 895–906.
21.
BisognanoJ, McLaughlinT, RobertsCSIncremental effectiveness of amlodipine besylate in the treatment of hypertension with single and multiple medication regimens. Am J Hypertens2004; 17: 676–83.
22.
WheltonPK, BarzilayJ, CushmanWCClinical outcomes in antihypertensive treatment of type 2 diabetes, impaired fasting glucose concentration, and normoglycemia: Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med2005; 165: 1401–9.
23.
EsnaultVL, BrownEA, ApetreiEThe effects of amlodipine and enalapril on renal function in adults with hypertension and nondiabetic nephropathies: a 3-year, randomized, multicenter, double-blind, placebo-controlled study. Clin Ther2008; 30: 482–98.
24.
RahmanM, PresselS, DavisBRRenal outcomes in high-risk hypertensive patients treated with an angiotensin-converting enzyme inhibitor or a calcium channel blocker vs a diuretic: a report from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Arch Intern Med2005; 165: 936–46.
25.
ElliottWJ, MeyerPM. Incident diabetes in clinical trials of antihypertensive drugs: a network meta-analysis. Lancet2007; 369: 201–7.
26.
LeinungMC. The role of calcium antagonists in the treatment of hypertension in patients with diabetes: a reappraisal based on recent evidence. The Endocrinologist2006; 16: 349–57.
27.
Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care1997;20:1183–97.
28.
Kidney Disease Outcomes Quality Initiative (K/DOQI).K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification. Am J Kidney Dis2002;39: S1–266.
29.
GoldbergA, SweetC.Efficacy and safety of losartan. Can J Cardiol1995; 11(suppl F):27F–32F.
30.
OlveraS, AlcocerL, NovoaG.Usefulness of low-dose, once-daily quinapril as monotherapy for patients with hypertension. Clin Ther1996; 18: 864–73.
31.
HendrixK, TangS, ThakkerK, FoxJ, EganB.Adding dihydropyridine calcium channel blocker lowers BP in diabetic hypertensives irrespective of baseline treatment and demographics. J Clin Hypertens2006; 8:A82(P-183).
32.
AgrawalR, MarxA, HallerH.Efficacy and safety of lercanidipine versus hydrochlorothiazide as add-on to enalapril in diabetic populations with uncontrolled hypertension. J Hypertens2006; 24: 185–92.
33.
ConlinPR, SpenceJD, WilliamsBAngiotensin II antagonists for hypertension: are there differences in efficacy?Am J Hypertens2000; 13: 418–26.
34.
NeutelJM, SmithDH, WeberMA. Low dose combination therapy vs high dose monotherapy in the management of hypertension. J Clin Hypertens (Greenwich)1999; 1: 79–86.
35.
TobeS, Kawecka-JaszczK, ZannadF, VetrovecG, PatniR, ShiH.Amlodipine added to quinapril vs quinapril alone for the treatment of hypertension in diabetes: the Amlodipine in Diabetes (ANDI) Trial. J Clin Hypertens (Greenwich)2007; 9: 120–7.
36.
MalaccoE, OmboniS.Antihypertensive efficacy of zofenopril plus hydrochlorothiazide fixed combination is superior to that of single components (abstract). Eur Heart J2005; 26: 401.
37.
NeutelJM, SmithDH, WeberMA, SchofieldL, PurkayasthaD, GatlinM.Efficacy of combination therapy for systolic blood pressure in patients with severe systolic hypertension: the Systolic Evaluation of Lotrel Efficacy and Comparative Therapies (SELECT) study. J Clin Hypertens (Greenwich)2005; 7:641–6; quiz 7–8.
38.
NathanS, PepineCJ, BakrisGL. Calcium antagonists: effects on cardiorenal risk in hypertensive patients. Hypertension2005; 46: 637–42.
39.
TurnbullF, NealB, AlgertCEffects of different blood pressure-lowering regimens on major cardiovascular events in individuals with and without diabetes mellitus: results of prospectively designed overviews of randomized trials. Arch Intern Med2005; 165: 1410–9.
